Here is the design of a clinical trial:

Official Title: Liberal Transfusion Strategy to Prevent Mortality and Anaemia-associated, Ischaemic Events in Elderly Non-cardiac Surgical Patients

Included conditions:
- Transfusion-dependent Anemia
- Surgery
- Anemia

Study Armgroups:
- {'label': 'Liberal', 'type': 'EXPERIMENTAL', 'description': 'Liberal group (patients receive a RBC unit each time Hb falls ≤ 9 g/dl (≤ 5.6mmol/l) with a target range for the post-transfusion Hb level of 9-10.5 g/dl (5.6-6.5 mmol/l)).', 'interventionNames': ['Drug: red blood cell transfusion trigger']}
- {'label': 'Restrictive', 'type': 'ACTIVE_COMPARATOR', 'description': 'Restrictive group (patients receive a single RBC unit each time Hb falls ≤ 7.5 g/dl (≤ 4.7 mmol/l) with a target range for the post-transfusion Hb level of 7.5-9 g/dl (4.7-5.6 mmol/l).', 'interventionNames': ['Drug: red blood cell transfusion trigger']}

Interventions:
- {'type': 'DRUG', 'name': 'red blood cell transfusion trigger', 'description': 'patients receive a RBC unit with different target ranges for the post-transfusion Hb levels', 'armGroupLabels': ['Liberal', 'Restrictive']}

Primary Outcomes:
- {'measure': 'Occurrence of a composite endpoint', 'description': 'Composite of death and anaemia-associated events I. All-cause mortality defined as death from any cause. II. Acute myocardial infarction confirmed by a cardiologist III. Acute ischaemic stroke confirmed by a neurologist IV. Acute kidney injury (stage III) defined according to the Kidney Disease Improving Global Outcomes criteria: Increase of plasma creatinine level ≥ 3 times within a time window of 7 days or initiation of renal replacement therapy.\n\nV. Acute mesenteric ischaemia defined as ischaemia confirmed by intervention (abdominal surgery or mesenteric angiography).\n\nVI. Acute peripheral vascular ischaemia defined as a new non-thrombotic compromised circulation in a limb confirmed by angiography and/or leading to surgery.', 'timeFrame': '90 days'}

Please estimate the sample size based on the assumption: 
A two-sided significance level of 5%, power of 80%, and a dropout rate of up to 5% are assumed.
Sample size considerations
        For the primary endpoint, we expect an overall composite complication rate (OCCR) of about 25% at 90âdays after surgery. This guestimate is based on a subgroup of elderly patients included in a large observational study in the field of Patient Blood Management [29], which reported most of the endpoint components, and is also based on the assumption that about 25â40% of registered patients will be randomised.
        The effect size to be detected is set to an odds ratio of ORâ=â0.765. The available evidence on treatment differences from randomised trials concerning the old age group is sparse and inconsistent. Therefore, we choose an effect size, which is relevant from a clinical perspective. Assuming an OCCR of 25%, an odds ratio of ORâ=â0.765, corresponding to a 5% reduction in OCCR from 27.5% to 22.5% or risk reduction of 18%, would justify switching to the liberal transfusion strategy.
        The target sample size is Nâ=â2470 randomised patients. Randomisation of 2âÃâ1176â=â2352 patients is required using a two-sided significance level of 5% and requiring power of 80% for a test of the null-hypothesis ORâ=â1 versus ORâ=â0.765 based on the normal approximation to log (OR). We allow for a dropout rate of up to 5%.